PVI
VKTX icon

Pura Vida Investments’s Viking Therapeutics VKTX Stock Holding History

Pura Vida Investments’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-100,000
Closed -$949K – 129
2018
Q2 		$949K Buy
+100,000
New +$665K 0.38% 71

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Pura Vida Investments's VKTX Position: Q2 2024 in Review

Pura Vida Investments sold out of Viking Therapeutics (VKTX) in Q2 2024, closing a stake of 39,868 shares — an estimated $3.27M sold.

Pura Vida Investments first reported a position in VKTX in Q4 2017 and held it in 4 quarters. The position peaked at $3.27M in Q1 2024. 387 funds tracked by Wall St. Rank hold VKTX as of Q2 2024.

  • Pura Vida Investments reported no remaining Viking Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Pura Vida Investments sold 39,868 Viking Therapeutics shares in Q2 2024, an estimated $3.27M.
  • Pura Vida Investments first reported a position in Viking Therapeutics in Q4 2017 and held it in 4 quarters.
  • Pura Vida Investments's Viking Therapeutics position peaked at $3.27M in Q1 2024.
  • 387 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2024.

Based on Pura Vida Investments's 13F filing for Q2 2024, filed 14 Aug 2024.